FDA D.I.S.C.O. Burst Edition: FDA approvals of Cytalux (pafolacianine) for identifying malignant ovarian cancer lesions and Darzalex Faspro (daratumumab + hyaluronidase-fihj), Kyprolis (carfilzomib) and dexamethasone for multiple myeloma
0:00
4:59
Listen to a soundcast of the November 29, 2021 and November 30, 2021 FDA approvals of Cytalux (pafolacianine) for identifying malignant ovarian cancer lesions and Darzalex Faspro (daratumumab + hyaluronidase-fihj), Kyprolis (carfilzomib) and dexamethasone for multiple myeloma.
Fler avsnitt från "FDA Drug Information Soundcast in Clinical Oncology (D.I.S.C.O.)"
Missa inte ett avsnitt av “FDA Drug Information Soundcast in Clinical Oncology (D.I.S.C.O.)” och prenumerera på det i GetPodcast-appen.